Can Johnson & Johnson’s Imbruvica Sales Beat Roche’s Rituxan In Chronic Lymphocytic Leukemia Market By 2021?
Johnson & Johnson’s (NYSE: JNJ) Imbruvica is poised to beat Roche’s top selling drug in the chronic lymphocytic leukemia drugs market over the next few years. This can be attributed to expected competition for Rituxan from biosimilars, given its market exclusivity period ended last year...